ARCT - アルコブラ (Arcturus Therapeutics Ltd.)

ARCTのニュース

   Arcturus Therapeutics Q2 2022 Earnings Preview (NASDAQ:ARCT)  2022/08/08 21:35:05 Seeking Alpha
Arcturus Therapeutics (ARCT) is scheduled to announce Q2 earnings results on Tuesday, August 9th, after market close.The consensus EPS Estimate is -$1.88 and the consensus Revenue…
   Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022  2022/08/01 20:00:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2022 after the market close on Tuesday, August 9 and will also host a conference call and webcast at 4:30 pm
   Stock Of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) Dropped By -2.46 Percent Over The Past Month, Is There Room For Downside?  2022/07/09 19:00:00 Marketing Sentinel
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)’s traded shares stood at 0.4 million during the last session, with the company’s beta value hitting 2.79. At the close of trading, the stock’s price was $19.06, to imply an increase of 0.58% or $0.11 in intraday trading. The ARCT share’s 52-week high remains $65.00, putting it -241.03% down since … Stock Of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) Dropped By -2.46 Percent Over The Past Month, Is There Room For Downside? Read More »
   OMER, ARCT and MVST among after hour mover  2022/06/30 21:35:07 Seeking Alpha
Gainers:Inter & (INTR) +34%. Cytokinetics (CYTK) +6%
   Arcturus gains on reports to draw takeover interest, blog report claims  2022/06/22 05:39:01 Seeking Alpha
Arcturus Therapeutics (ARCT) is said to have been approached about a takeover by CSL Limited (CSLLY), a source reportedly told Street Insider, whose account added that it is "unclear if…
   Benzinga''s Top Ratings Upgrades, Downgrades For May 11, 2022  2022/05/11 14:02:45 Benzinga
Upgrades According to Roth Capital, the prior rating for Hecla Mining Co (NYSE: HL ) was changed from Neutral to Buy. In the first quarter, Hecla Mining showed an EPS of $0.01, compared to $0.06 from the year-ago quarter. The stock has a 52-week-high of $9.44 and a 52-week-low of $4.28. At the end of the last trading period, Hecla Mining closed at $4.36. According to Zelman, the prior rating for The AZEK Co Inc (NYSE: AZEK ) was changed from Hold to Buy. For the second quarter, AZEK Co had an EPS of $0.33, compared to year-ago quarter EPS of $0.25. At the moment, the stock has a 52-week-high of $50.65 and a 52-week-low of $17.00. AZEK Co closed at $17.33 at the end of the last trading period. According to Maxim Group, the prior rating for Celsius Holdings Inc (NASDAQ: CELH ) was changed from Hold to Buy. In the first quarter, Celsius Holdings showed an EPS of $0.09, compared to $0.01 from the year-ago quarter. The stock has a 52-week-high of $110.22 and a 52-week-low of $38.31. At the end of the last trading period, Celsius Holdings closed at $41.31.
   Expert Ratings for Arcturus Therapeutics  2022/05/10 20:58:08 Benzinga
Within the last quarter, Arcturus Therapeutics (NASDAQ: ARCT ) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 2 1 1 0 Last 30D 0 0 1 1 0 1M Ago 0 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 0 1 0 0 0 These 5 analysts have an average price target of $66.8 versus the current price of Arcturus Therapeutics at $16.485, implying upside. Below is a summary of how these 5 analysts rated Arcturus Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on … Full story available on Benzinga.com
   Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q1 2022 Results - Earnings Call Transcript  2022/05/10 03:09:06 Seeking Alpha
Arcturus Therapeutics Holdings Inc. (NASDAQ:NASDAQ:ARCT) Q1 2022 Results Earnings Conference Call May 9, 2022, 04:30 PM ET Company Participants Deepankar Roy - Senior Director, Investor…
   Arcturus Therapeutics GAAP EPS of -$1.94 misses by $0.63, revenue of $5.24M misses by $1.84M  2022/05/09 20:31:42 Seeking Alpha
Arcturus Therapeutics press release (NASDAQ:ARCT): Q1 GAAP EPS of -$1.94 misses by $0.63.Revenue of $5.24M (+146.0% Y/Y) misses by $1.84M.
   Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress  2022/05/09 20:00:00 Wallstreet:Online
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the first quarter ended March 31, 2022, and provided corporate updates. This
   Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ...  2021/12/24 05:38:01 GuruFocus
Related Stocks: BIIB , IKNA , ABBV , GLPG , SIBN , LUNG , ADGI , ZBH , HCA , ERAS , SGEN , CTKB , PRLD , NTRA , ANTM , AFIB , ABCL , DCPH , AUPH , ASND , TRIL , ARCT , ALXN , ALEC ,
   Arcturus Therapeutics (NASDAQ:ARCT) Shares Gap Up to $42.65  2021/12/23 15:54:45 Dakota Financial News
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)s share price gapped up before the market opened on Thursday . The stock had previously closed at $42.65, but opened at $43.86. Arcturus Therapeutics shares last traded at $42.00, with a volume of 2,855 shares. ARCT has been the subject of a number of analyst reports. Barclays decreased their price []
   Brokerages Expect Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Will Post Quarterly Sales of $12.90 Million  2021/12/22 07:50:44 Transcript Daily
Brokerages predict that Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) will report sales of $12.90 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Arcturus Therapeutics earnings, with the lowest sales estimate coming in at $1.50 million and the highest estimate coming in at $43.40 million. Arcturus Therapeutics reported sales []
   Arcturus Therapeutics (NASDAQ:ARCT) Trading Up 8.9%  2021/12/17 17:40:41 Dakota Financial News
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) was up 8.9% during trading on Friday . The stock traded as high as $46.88 and last traded at $46.83. Approximately 19,475 shares changed hands during trading, a decline of 98% from the average daily volume of 825,301 shares. The stock had previously closed at $43.00. Several research analysts have []
   Brokerages Anticipate Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) to Post -$1.81 Earnings Per Share  2021/12/05 15:46:42 Transcript Daily
Equities research analysts expect Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) to report ($1.81) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Arcturus Therapeutics earnings, with estimates ranging from ($2.31) to ($0.80). Arcturus Therapeutics posted earnings of ($1.25) per share in the same quarter last year, which []

calendar